Results 241 to 250 of about 22,583 (294)
Radiopharmaceutical stannic Sn-117m chelate compositions and methods of use
, 2001 S.C. Srivastava, George E Meinken
openalex +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Adverse reactions to radiopharmaceuticals: liver radiopharmaceuticals
Nuclear Medicine Communications, 2021Radiopharmaceuticals are radioactive compounds used in nuclear medicine, consisting of a radioactive moiety and a pharmaceutical part. Radiopharmaceuticals are used for diagnosis (predominantly) and therapy (to a lesser extent). Adverse drug reactions are undesirable, unexpected, often harmful drug responses that occur when the drug is administered in ...
Humeyra Battal, Asuman Yekta Ozer
openaire +2 more sources
Pitfalls With Radiopharmaceuticals
The American Journal of the Medical Sciences, 2011There is a considerable body of evidence describing that the pharmacokinetics and pharmacodynamics of radiopharmaceuticals may be changed by a variety of drugs, disease states and in some cases, surgical procedures.: To systematically search the medical literature and review the published evidence on adverse reactions to radiopharmaceuticals.MEDLINE ...
Márcio Machado, Ralph Santos-Oliveira
openaire +3 more sources
Bispidines for radiopharmaceuticals
Dalton Transactions, 2018Radiometal based radiopharmaceuticals for imaging and therapy require selective ligands (bifunctional chelators, BFCs) that form metal complexes, which are inert againsttrans-chelation under physiological conditions, linked to a biological vector, directing them to the targeted tissue.
Peter Comba +3 more
openaire +3 more sources
Radiopharmaceuticals for Neuroendocrine Tumors
Seminars in Radiation Oncology, 2021Neuroendocrine tumors (NETs) are a heterogeneous group of tumors that originate in endocrine tissues throughout the body. Peptide receptor radionuclide therapy (PRRT) has emerged as a promising therapeutic option for patients with locally advanced and/or metastatic disease refractory to standard of care treatment.
Hyun Jik Kim +3 more
openaire +3 more sources
The Regulation of Radiopharmaceuticals
JAMA: The Journal of the American Medical Association, 1985To the Editor.— The recent editorial on the Food and Drug Administration's (FDA) role in the drug approval process is appropriate. 1 In our opinion, the FDA has shown concern about infringement upon the practice of medicine. 2 Such may not be said for the Nuclear Regulatory Commission (NRC), in its interpretation of its statutory authority to regulate
openaire +3 more sources
SPECT Radiopharmaceuticals for Dementia
Current Radiopharmaceuticals, 2014Over the last decade the interest towards functional neuroimaging has gradually increased, especially in the field of neurodegenerative diseases. At present, diagnosis of dementia is mostly clinical. Numerous modalities of neuroimaging are today available, each of them allowing a different aspect of neurodegeneration to be investigated. Although during
Guidotti, Claudio +6 more
openaire +3 more sources
Radiopharmaceuticals labelled with Technetium
The International Journal of Applied Radiation and Isotopes, 1977Abstract The ready availability and ideal nuclear properties of 99mTc has led to its widespread use for imaging purposes. In general the localization of the present radiopharmaceuticals is based on the ability of an organ to remove foreign substances from the blood. Further application of this ideal nuclide seems related to the development of methods
Stanley M. Levenson, W. C. Eckelman
openaire +3 more sources
Radiopharmaceutical Dosimetry in Pediatrics
Radiology, 1968The increasing use of radionuclides in medical diagnosis and research requires that we investigate further the radiation exposure from these procedures. Although information is frequently available for adults (1–3), only occasional reference is found to radiation doses received by children (4), a group in which there should be much concern about ...
James G. Kereiakes +3 more
openaire +5 more sources
Renal radiopharmaceuticals—An update
Seminars in Nuclear Medicine, 1982Noninvasive radionuclide procedures in the evaluation of renal disease have been accepted increasingly as effective and valuable alternatives to older clinical methods. The development of suitable radiopharmaceuticals labeled with high photon intensity radionuclides and with 99mTc in particular has stimulated this modality during the last few years ...
L. Rao Chervu, M. Donald Blaufox
openaire +4 more sources